Doctor testimonials — Biologic Eye Drops

QUESTIONS about biologic eye drops? Call the FDA.

Biologics division 800-835-4709 option 1.

OTC division 855-543-3784 option 4.

Skip to Content

Report problems to the FDA

Report deceptive advertising

A Patient's Story

DrB's Educational Presentations

Non-Preserved Eye Drop Safety

The Placebo Effect

On Label, Off Label or No Label?

Placentas from Strangers

Product Recalls (Dec 10, 2024)

DEF Open Letter to Key Opinion Leaders (Nov 7, 2024)

FDA Warning Letter to Regenerative Processing Plant (Aug 16, 2024)

FDA Warning Letter to Neobiosis (June 5, 2024)

FDA Inspection Form 483 - RPP Tampa (June 23, 2023)

FDA Inspection Form 483 - RPP Palm Harbor (June 30, 2023)

DEF Open Letter to the FDA (May 12, 2023)

DEF Open Letter to the Eye Care Press (May 5, 2023)

DEF Open Letter to ABB Optical and Dry Eye Rescue (May 1, 2023)

FDA Public Safety Notification on Amniotic Fluid Eyedrops (Apr 10, 2023)

DEF Open Letter re StimulEyes (Mar 9, 2023)

DEF Open Letter to Regener-Eyes (Mar 5, 2023)

FDA Untitled Letter re StimulEyes (Nov 17, 2022)

FDA Untitled Letter to Regener-Eyes (Oct 5, 2022)

DEF Open Letter to Regener-Eyes (Sep 29, 2022)

DEF Regulatory Compliance Summary Information (June 8, 2022)

DEF Open letter for Eye Care Professionals (May 16, 2022)

Report problems to the FDA

Report deceptive advertising

A Patient's Story

DrB's Educational Presentations

Non-Preserved Eye Drop Safety

The Placebo Effect

On Label, Off Label or No Label?

Placentas from Strangers

Product Recalls (Dec 10, 2024)

DEF Open Letter to Key Opinion Leaders (Nov 7, 2024)

FDA Warning Letter to Regenerative Processing Plant (Aug 16, 2024)

FDA Warning Letter to Neobiosis (June 5, 2024)

FDA Inspection Form 483 - RPP Tampa (June 23, 2023)

FDA Inspection Form 483 - RPP Palm Harbor (June 30, 2023)

DEF Open Letter to the FDA (May 12, 2023)

DEF Open Letter to the Eye Care Press (May 5, 2023)

DEF Open Letter to ABB Optical and Dry Eye Rescue (May 1, 2023)

FDA Public Safety Notification on Amniotic Fluid Eyedrops (Apr 10, 2023)

DEF Open Letter re StimulEyes (Mar 9, 2023)

DEF Open Letter to Regener-Eyes (Mar 5, 2023)

FDA Untitled Letter re StimulEyes (Nov 17, 2022)

FDA Untitled Letter to Regener-Eyes (Oct 5, 2022)

DEF Open Letter to Regener-Eyes (Sep 29, 2022)

DEF Regulatory Compliance Summary Information (June 8, 2022)

DEF Open letter for Eye Care Professionals (May 16, 2022)

Report problems to the FDA

Report deceptive advertising

Folder: Watch & Learn

A Patient's Story

DrB's Educational Presentations

Non-Preserved Eye Drop Safety

The Placebo Effect

On Label, Off Label or No Label?

Placentas from Strangers

Folder: History

Product Recalls (Dec 10, 2024)

DEF Open Letter to Key Opinion Leaders (Nov 7, 2024)

FDA Warning Letter to Regenerative Processing Plant (Aug 16, 2024)

FDA Warning Letter to Neobiosis (June 5, 2024)

FDA Inspection Form 483 - RPP Tampa (June 23, 2023)

FDA Inspection Form 483 - RPP Palm Harbor (June 30, 2023)

DEF Open Letter to the FDA (May 12, 2023)

DEF Open Letter to the Eye Care Press (May 5, 2023)

DEF Open Letter to ABB Optical and Dry Eye Rescue (May 1, 2023)

FDA Public Safety Notification on Amniotic Fluid Eyedrops (Apr 10, 2023)

DEF Open Letter re StimulEyes (Mar 9, 2023)

DEF Open Letter to Regener-Eyes (Mar 5, 2023)

FDA Untitled Letter re StimulEyes (Nov 17, 2022)

FDA Untitled Letter to Regener-Eyes (Oct 5, 2022)

DEF Open Letter to Regener-Eyes (Sep 29, 2022)

DEF Regulatory Compliance Summary Information (June 8, 2022)

DEF Open letter for Eye Care Professionals (May 16, 2022)

Testimonials from doctors

Regener-Eyes

StimulEyes

Join Dry Eye Foundation mailing list(s)

Copyright © 2026. All rights reserved.